Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom
July 21 2021 - 8:55AM
InvestorsHub NewsWire
NEW YORK, NY -- July 21, 2021 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a New York based diversified Life
Sciences Company, today announced that it has commenced sales of
its Tauri-Gum™ product line in the United Kingdom. In
addition, the Company has retained a full-time salesperson -
located in London. The Company expects to substantially
increase its sales, in the United Kingdom, throughout the remainder
of Calendar Year 2021 and
beyond.
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc. (TAUG) is a revenue
generating, diversified life sciences company, engaged in several
major business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main
product line, branded as Tauri-Gum™, consists of a proprietary
supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood
Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon,
Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear
Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey),
& (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden
Raspberry). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce
website: www.taurigum.com). Please visit our corporate
website, for additional information, as well as inquiries,
at http://www.tauriga.com
Complementary to the Company’s retail business, is
its ongoing Pharmaceutical Development initiative. This
relates to the development of a proposed Pharmaceutical grade
version of Tauri-Gum™, for nausea regulation (specifically designed
for the following indication: Patients Subjected to Ongoing
Chemotherapy Treatment). On March 22, 2021, the Company announced
that it had Converted its U.S. Provisional Patent Application
(filed on March 17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development
efforts.
The Company is headquartered in Wappingers Falls,
New York. In addition, the Company operates two full
time E-Commerce fulfillment centers: one located in Montgomery,
Texas and the other in Brooklyn, New
York.
DISCLAIMER -- Forward-Looking
Statements
This press release contains certain
“forward-looking statements” as defined by the Private Securities
Litigation Reform Act of 1995 which represent management’s beliefs
and assumptions concerning future events. These forward-looking
statements are often indicated by using words such as “may,”
“will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as
well as the attainment of certain corporate goals and milestones.
Forward-looking statements are based on present circumstances and
on management’s present beliefs with respect to events that have
not occurred, that may not occur, or that may occur with different
consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed
in forward looking statements due to known and unknown
risks and uncertainties, such as are not guarantees of general
economic and business conditions, the ability to successfully
develop and market products, consumer and business consumption
habits, the ability to consummate successful acquisition and
licensing transactions, fluctuations in exchange rates, and other
factors over which Tauriga has little or no control. Many of these
risks and uncertainties are discussed in greater detail in the
“Risk Factors” section of Tauriga’s Form 10-K and other periodic
filings made from time to time with the Securities and Exchange
Commission. Such forward-looking statements are made only as of the
date of this release, and Tauriga assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these
forward-looking
statements.
Contact:
Tauriga Sciences,
Inc.
4
Nancy Court, Suite 4
Wappingers Falls, NY
12590
Chief Executive
Officer
Mr. Seth M.
Shaw
Email: sshaw@tauriga.com
cell # (917) 796
9926
Company Instagram:
@taurigum
Personal
Instagram: @sethsms47
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024